Refine
Has Fulltext
- yes (15)
Is part of the Bibliography
- yes (15)
Document Type
- Journal article (15)
Language
- English (15)
Keywords
- blood–brain barrier (6)
- endothelial cells (4)
- tight junctions (3)
- age-related hearing loss (2)
- blood-brain barrier (2)
- blood–labyrinth barrier (2)
- cEND (2)
- heart failure (2)
- in vitro (2)
- inflammation (2)
- neurotrophins (2)
- spiral ganglion neuron (2)
- Alzheimer's disease (1)
- Alzheimer’s disease (1)
- BDNF (1)
- Blut-Hirn-Schranke (1)
- CNS diseases (1)
- CNS disorders (1)
- CNS injury (1)
- GDNF (1)
- Glucosetransportproteine (1)
- IL-6 (1)
- IL6 (1)
- MK801 (1)
- NF-kappa-B (1)
- NMDA-Antagonist (1)
- NMDA-Rezeptor (1)
- NMDAR (1)
- PIK3R1 (1)
- Schlaganfall (1)
- TNF-α (1)
- TTFields (1)
- TTS (1)
- Takotsubo syndrome (1)
- aging (1)
- alzheimer's disease (1)
- amyloid cardiomyopathy (1)
- angiogenesis (1)
- approved drugs (1)
- astrocytes (1)
- barrier (1)
- barrier properties (1)
- blood (1)
- blood brain barrier (1)
- brain (1)
- brain pathology (1)
- calcium level (1)
- cell stretch (1)
- central nervous system (1)
- cerebEND (1)
- cerebral ischemia (1)
- chemical similarity (1)
- corticosteroids (1)
- cytokine expression (1)
- dexamethasone (1)
- diabetes mellitus (1)
- diabetic nephropathy (1)
- diabetic retinopathy (1)
- drug repurposing (1)
- drug transporter (1)
- exposure (1)
- expression (1)
- fetal lung (1)
- glucocorticoid receptor (1)
- glucocorticoids (1)
- glut1 (1)
- human (1)
- immortalization (1)
- immunology (1)
- in vitro cell culture models (1)
- in vitro model (1)
- inner ear (1)
- ischemia (1)
- isosteviol sodium (STVNA) (1)
- kidney ischemia/reperfusion injury (1)
- lipids (1)
- microRNA (1)
- microvascular complications (1)
- microvascular endothelial cells (1)
- molecular modeling (1)
- mouse models (1)
- necrosis factor alpha (1)
- nervous system (1)
- neuroscience (1)
- neurotrophic factor (1)
- neurovasculature (1)
- nitric oxide (1)
- oxygen-glucose deprivation (1)
- patient (1)
- pharmacotherapy (1)
- phosphatidylinositol (1)
- pregnancy (1)
- preterm birth (1)
- protein expression (1)
- rat (1)
- receptor antagonist (1)
- scaffold search (1)
- senescence (1)
- sglt1 (1)
- sheep (1)
- stroke (1)
- subarachnoid hemorrhage (1)
- traumatic brain injury (1)
Institute
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (15)
- Institut für Anatomie und Zellbiologie (4)
- Neurochirurgische Klinik und Poliklinik (3)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
- Medizinische Klinik und Poliklinik I (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
EU-Project number / Contract (GA) number
- 241778 (3)
- HEALTH-F2-2009-241778 (1)
Alzheimer’s disease (AD), the most common cause of dementia in the elderly, is a neurodegenerative disorder associated with neurovascular dysfunction, cognitive decline, and the accumulation of amyloid β peptide (Aβ) in the brain and tau-related lesions in neurons termed neurofibrillary tangles (NFTs). Aβ deposits and NFT formation are the central pathological hallmarks in AD brains, and the majority of AD cases have been shown to exhibit a complex combination of systemic comorbidities. While AD is the foremost common cause of dementia in the elderly, age-related hearing loss (ARHL) is the most predominant sensory deficit in the elderly. During aging, chronic inflammation and resulting endothelial dysfunction have been described and might be key contributors to AD; we discuss an intriguing possible link between inner ear strial microvascular pathology and blood–brain barrier pathology and present ARHL as a potentially modifiable and treatable risk factor for AD development. We present compelling evidence that ARHL might well be seen as an important risk factor in AD development: progressive hearing impairment, leading to social isolation, and its comorbidities, such as frailty, falls, and late-onset depression, link ARHL with cognitive decline and increased risk of dementia, rendering it tempting to speculate that ARHL might be a potential common molecular and pathological trigger for AD. Additionally, one could speculate that amyloid-beta might damage the blood–labyrinth barrier as it does to the blood–brain barrier, leading to ARHL pathology. Finally, there are options for the treatment of ARHL by targeted neurotrophic factor supplementation to the cochlea to improve cognitive outcomes; they can also prevent AD development and AD-related comorbidity in the future.